EGFR and cancer: Therefore, the novelties of this study are as follows: (i) this is the first study to report the anti-angiogenic effects of HAT and elucidate its underlying mechanism, and (ii) this study focused on the multifaceted action of HAT on the complex crosstalk between ECs and cancer cells to regulate EGFR TKI resistance.